Navigation Links
VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to Present at Third Annual Clinical and Surgical Translation of Stem Cells
Date:10/22/2015

VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to present veterinary perspective on stem cell therapy at Third Annual Clinical and Surgical Translation of Stem Cells.

Robert Harman, DVM, Founder and CEO of Regenerative Veterinary Medicine company VetStem Biopharma, Inc. is scheduled to speak at the Third Annual Clinical and Surgical Translation of Stem Cells Conference, November 10th in San Diego, California.

Dr. Harman will present a veterinary perspective on stem cell therapy from VetStem’s clinical experience with 11,000 cases. As a leader in stem cell science and translation to the clinic, Dr. Harman will showcase clinical experiences in 1000’s of veterinary clinics across the US and Canada and provide insights in efficacy, safety, and medical acceptance in human medical field. He will cover clinical experiences and study data from both orthopedics and internal medicine cases.

The conference brings together basic scientists and clinician-scientists, as well as medical practitioners and surgeons focusing on studying, characterizing, and deploying various classes of adult stem cells for therapeutic utility.

“The opportunity to speak at such a prestigious conference right here in our home city is an honor and further recognition by the human regenerative medicine community of the value of veterinary clinical experience and contributions we have provided to the field of regenerative medicine over the past 12 years, with over 11,000 animal patients treated,” stated Dr. Harman.

VetStem first pioneered adipose derived stem cell therapy for use in horses for tendon injuries, as an alternative to euthanasia. Just two years after the first horse was treated, VetStem treated the first cat and dog. In 2007 the first peer reviewed, randomized, double-blinded, placebo controlled, multi-center study was published showing intra-articular injection of adipose derived stem cells in the hip joint of a dog decreased patient discomfort and increased patient functional ability. That same year Vet-Stem brought to market the Genesis Platelet Rich Plasma concentration system, as well as the first formal small animal stem cell credentialing course. In 2015, VetStem (now VetStem Biopharma) has announced the successful completion of a pilot efficacy study for allogeneic stem cell therapy (90 dogs, multi-center, blinded, placebo controlled) in support of an FDA INAD. Primary end point was statistically significant. The study will be submitted for peer reviewed publication.

About VetStem Biopharma
VetStem Biopharma is a veterinarian lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, Vet-Stem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.

Contact:
Kristi Hauta
Marketing Operations Manager
VetStem Biopharma
Ph (858) 748-2004 ext 208
12860 Danielson Court, Suite B
Poway, CA 92064
http://www.vetstem.com

Read the full story at http://www.prweb.com/releases/2015/10/prweb13033225.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved


Related biology technology :

1. Advanced Care Veterinary Services is Now Offering Stem Cell Therapy for Dogs and Cats in Conjunction with VetStem Biopharma
2. VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease
3. VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015
4. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to be a Guest Speaker at MSC 2015 Adult Stem Cell Therapy & Regenerative Medicine Conference
5. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
6. VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour
7. VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center.
8. VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities.
9. VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering
10. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, Announces the Addition of Dr Ross Rich as the Director of Clinical Development
11. West Coast Bird Dog Champion Wins US Bird Dog Association Western States National Flushing Champion with the help of Stem Cell Therapy by VetStem.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... ... ... was adopted from a local shelter when he was around two years old. According ... weeks after he was adopted, he tore his right cruciate ligament. Though he had ... such a traumatic injury. , Sure enough, when Rascal was about nine years old, he ...
(Date:1/8/2019)... DENVER (PRWEB) , ... January 07, 2019 , ... ... comprised of its members into Noninvasix. This represents the second investment AngelMD has ... neonatal mortality and morbidity, Noninvasix is developing a patient monitor to directly, accurately, ...
(Date:1/4/2019)... TRIANGLE PARK, N.C. (PRWEB) , ... January 04, ... ... consulting organization, is pleased to welcome Ted Hoffman to the firm. Ted will ... 20 years of experience working in and providing consulting services to the pharmaceutical ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, ... cancer, today announced the founding of a scientific and medical advisory board (SMAB). ... key leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB ...
Breaking Biology Technology:
(Date:12/18/2018)... ... December 18, 2018 , ... CP Merritt is a national champion ... for many years however in 2006, he had a medical setback that caused him ... that he suffered from cartilage degeneration in his right rear fetlock. Such an ...
(Date:12/13/2018)... ... December 13, 2018 , ... Study Protocol Summary of ... (with Ethical e-CRF®): IGA first assessment performed at the site., 3 - Three photos ... Staff Controls Photo anonymization in BOX., 5 - Photos moved to eAdjudication® and submitted ...
(Date:12/13/2018)... ... December 12, 2018 , ... Royal Biologics, an ... has announced the launch of Maxx-Cell, the world's most advanced bone marrow aspiration ... aspirating a patients autologous bone marrow cells. Maxx™-Cell however does not require centrifugation ...
Breaking Biology News(10 mins):